Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus indacaterol, glycopyrronium, tiotropium, and placebo in moderate to severe COPD
NL-OMON36628Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium, glycopyrronium, indacaterol and tiotropium in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 at 26 weeks. Started Feb 2011; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumglycopyrroniumindacateroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON36628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36628.